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ABSTRACT 
The prevalence of CMV antibody of IgG and IgM isotypes among 
pretrasplant kidney recipient (group 1), kidney candidate donors (group 2) 
and healthy blood donors (group 3) was studied at Ahmed Gasim cardiac 
surgery and Renal Transplant Centre in Khartoum North, between January 
and December 2005. Blood samples were collected from the various groups 
and sera, were screened by indirect ELISA for group 1, 2 and 3 and 
Immuno chromatography test (ICT) for group 4, 5 and 6 for the presence of 
CMV antibodies using the appropriate conjugate of antihuman (Fc) portion 
of the respective immunoglobulin class. 
Pretransplant screening of the kidney patients waiting renal transplant 
(group 1) revealed that 96% of the patients have IgG CMV antibodies and 
10% have IgM antibodies. Significant high titer of IgG (OD> 2.0) probably 
indicates repeated infection or reactivation of latent infection, where as IgM 
antibodies indicate recurrent primary infection. In the healthy kidney 
candidate donors (Group 2) 92% showed the presence of the IgG antibody 
to CMV and 17 % revealed the presence of IgM. On the other hand the 
presence of CMV antibodies in healthy blood donors (group 3) was 84% for 
1gG and 22% for 1gM. We also observed that the presence of 1gM 
antibodies varied in the various age groups. It was high in children and 
young adult and was almost absent in elderly suggesting that seroconvertion 
is an ongoing process. 
The prevalence of CMV IgG antibodies were also determined using 
ICT, in kidney candidate recipients (group 4), healthy kidney candidate 
 xi
donors (group 5), healthy blood donor (group 6), were found 92.5%, 87.5% 
and 82.5%, respectively. The correlation between ICT and ELISA for the 
detection of CMV IgG antibodies was 96%. Therefore, both assay were 
sensitive and specific for the detection of CMV IgG antibodies.  
From this study it appeared that the high prevalence of CMV 
infection in the various groups studied might contribute to organ transplant 
rejection.  
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣـﺔ
اﺳﺔ ﻓﻲ ﻣﺴﺘﺸﻔﻰ أﺣﻤﺪ ﻗﺎﺳﻢ ﻣﺮآﺰ ﺟﺮاﺣﺔ اﻟﻘﻠﺐ وزراﻋﺔ اﻟﻜﻠﻰ ﺑﻤﻨﻄﻘﺔ ﺗﻢ إﺟﺮاء هﺬﻩ اﻟﺪر  
وذﻟﻚ ﻟﻘﻴﺎس ﻣﻌﻴﺎر اﻷﺟﺴﺎم اﻟﻤﻀﺎدة . م5002اﻟﺨﺮﻃﻮم ﺑﺤﺮي ﻓﻲ اﻟﻔﺘﺮة ﻣﺎ ﺑﻴﻦ ﻳﻨﺎﻳﺮ إﻟﻰ دﻳﺴﻤﺒﺮ 
ﻤﺠﻤﻮﻋﺔ ﻣﺴﺘﻘﺒﻠﻲ اﻟﻜﻠﻰ ﻣﺎ ﻗﺒﻞ اﻟﺰراﻋﺔ ﻟ( م)و(  ج )ﺻﻨﻔﻲﻟﻠﻔﻴﺮوس اﻟﻤﻀﺨﻢ ﻟﻠﺨﻼﻳﺎ ﻣﻦ 
وأﺷﺨﺎص أﺻﺤﺎء ﻣﺘﺒﺮﻋﻴﻦ ﺑﺎﻟﺪم "( 2"اﻟﻤﺠﻤﻮﻋﺔ )ﻋﻴﻦ ﺑﺎﻟﻜﻠﻰ ، وﻣﺠﻤﻮﻋﺔ اﻟﻤﺘﺒﺮ"(1"اﻟﻤﺠﻤﻮﻋﺔ )
ﺘﻲ ﻢ ﺟﻤﻊ ﻋﻴﻨﺎت اﻟﺪم ﻣﻦ اﻟﻤﺠﻤﻮﻋﺎت اﻟﻤﺨﺘﻠﻔﺔ وأﺟﺮي اﻟﻔﺤﺺ ﺑﻮاﺳﻄﺔ ﻃﺮﻳﻘﺗ"(. 3"اﻟﻤﺠﻤﻮﻋﺔ )
  اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻠﻔﻴﺮوس اﻟﻤﻀﺨﻢ ﻟﻠﺨﻼﻳﺎﻟﻘﻴﺎس وذﻟﻚ  واﻟﻘﻴﺎس اﻟﻠﻮﻧﻲ اﻟﻤﻤﻨﻊاﻹﻟﻴﺰا اﻟﻐﻴﺮ ﻣﺒﺎﺷﺮة
ﻷﻧﺘﺠﻴﻨﺎت ﻜﻞ ﻣﻦ هﺬﻳﻦ اﻟﺼﻨﻔﻴﻦ ﻣﺴﺘﻌﻤﻠﻴﻦ اﺠﺰء اﻟﺒﻠﻮري ﻟ اﻟﺑﺎﺳﺘﺨﺪام MgI، GgI ﻲ ﺻﻨﻔﻦﻣ
 .ﻟﻠﻔﻴﺮوس ﻟﻄﻼء اﻻﻃﺒﺎقاﻟﻤﺆﺷﺒﻪ 
% 01ﻟﻠﻔﻴﺮوس و( ج)ﻣﻦ اﻟﻤﺠﻤﻮﻋﺔ اﻷوﻟﻰ ﻟﺪﻳﻬﻢ أﺟﺴﺎم ﻣﻀﺎدة ﻣﻦ اﻟﻨﻮع % 69أن ﻧﺎ وﺟﺪ
وﻗﺪ وﺟﺪ أﻧﻪ ﻓﻲ ﺣﺎﻟﺔ زﻳﺎدة ﻣﻌﻴﺎر اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻓﻲ . ﻟﻠﻔﻴﺮوس( م)ﻟﺪﻳﻬﻢ أﺟﺴﺎم ﻣﻀﺎدة ﻣﻦ اﻟﻨﻮع 
، ﻣﻦ اﻟﻤﺤﺘﻤﻞ أن ﻳﻜﻮن دﻻﻟﺔ ﻋﻠﻰ إﺻﺎﺑﺔ ﻣﺘﻜﺮرة أو إﻋﺎدة ﺗﻨﺸﻴﻂ ﻟﻌﺪوى (0.2أآﺜﺮ ﻣﻦ ( )ج)اﻟﻨﻮع 
 .ﻳﺪل ﻋﻠﻰ ﻋﺪوى إﺑﺘﺪاﺋﻴﺔ ﻣﺘﻜﺮرة( م)أﻣﺎ ﻓﻲ ﺣﺎﻟﺔ اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻣﻦ اﻟﻨﻮع . ﺳﺎﺑﻘﺔ
 ﻟﺪﻳﻬﻢﻣﻨﻬﻢ % 29اﻟﻤﺘﺒﺮﻋﻴﻦ ﺑﺎﻟﻜﻠﻰ وﺟﺪ أن اﻷﺻﺤﺎء اﻷﺷﺨﺎص ( 2)ﻓﻲ ﺣﺎﻟﺔ اﻟﻤﺠﻤﻮﻋﺔ 
اﻷﺟﺴﺎم ﺑﻴﻨﻤﺎ ( م) أﺟﺴﺎم ﻣﻀﺎدة ﻣﻦ اﻟﻨﻮع  ﻟﺪﻳﻬﻢ%71ﻟﻠﻔﻴﺮوس و( ج)أﺟﺴﺎم ﻣﻀﺎدة ﻣﻦ اﻟﻨﻮع 
( ج)ﻣﻦ اﻟﻨﻮع % 48ﻳﻌﺎدل ( 3)ﻷﺷﺨﺎص اﻟﻤﺘﺒﺮﻋﻴﻦ ﺑﺎﻟﺪم اﻟﻤﺠﻤﻮﻋﺔ  ﻟﻠﻔﻴﺮوس ﻋﻨﺪاﻟﻤﻀﺎدة 
( 053)ﻟﻤﺠﻤﻮﻋﺎت اﻟﺜﻼث ﻣﺠﺘﻤﻌﺔ ﻓﻲ ااﻧﺘﺸﺎر اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻠﻔﻴﺮوس  (.م)ﻣﻦ اﻟﻨﻮع % 22و
وﻗﺪ ﻟﻮﺣﻆ ﻣﻦ ﺧﻼل اﻟﺪراﺳﺔ أن اﻷﺟﺴﺎم اﻟﻤﻀﺎدة (. م)ﻣﻦ اﻟﻨﻮع % 71( ج)ﻣﻦ اﻟﻨﻮع % 98ﻳﻌﺎدل 
ﻟﺠﻤﻴﻊ اﻟﻤﺠﻮﻋﺎت آﺎﻧﺖ ﺑﻨﺴﺒﺔ ﻣﺮﺗﻔﻌﺔ ﻓﻲ اﻷﻃﻔﺎل واﻟﺸﺒﺎب اﻟﺒﺎﻟﻐﻴﻦ وﺗﺨﺘﻔﻲ ﻓﻲ آﺒﺎر ( م)ﻣﻦ اﻟﻨﻮع 
  .اﻟﺴﻦ ﻣﻤﺎ ﻳﺪل ﻋﻠﻰ أن ﻋﻤﻠﻴﺔ إﻋﺎدة ﺗﻨﺸﻴﻂ اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﺗﺘﻢ ﺑﺼﻮرة ﻣﻨﺘﻈﻤﺔ
ﺑﺎﺳﺘﺨﺪام اﻟﻘﻴﺎس اﻟﻠﻮﻧﻲ اﻟﻤﻤﻨﻊ ( ج)ﺴﺎم اﻟﻤﻀﺎدة ﻣﻦ اﻟﻨﻮع وﻗﺪ أﺟﺮي اﻟﻜﺸﻒ ﻋﻦ أﺟ
 واﻷﺷﺨﺎص اﻷﺻﺤﺎء اﻟﻤﺘﺒﺮﻋﻴﻦ ﺑﺎﻟﻜﻠﻲ( 4ﻣﺠﻤﻮﻋﺔ )ﻟﻤﺠﻤﻮﻋﺔ ﻣﺴﺘﻘﺒﻠﻲ اﻟﻜﻠﻲ ﻗﺒﻞ اﻟﺰراﻋﺔ 
ﻋﻠﻰ % 5.28و % 5.78، %5.29وآﺎﻧﺖ اﻟﻨﺘﻴﺠﺔ ( 6ﻣﺠﻤﻮﻋﺔ ) واﻟﻤﺘﺒﺮﻋﻴﻦ ﺑﺎﻟﺪم (5ﻣﺠﻤﻮﻋﺔ )
%( 98)واﻷﻟﻴﺰا اﻟﻐﻴﺮ ﻣﺒﺎﺷﺮة %( 58) اﻟﻤﻤﻨﻊ ﻋﻨﺪ ﻣﻘﺎرﻧﺔ ﺑﻴﻦ ﻃﺮﻳﻘﺘﻲ اﻟﻘﻴﺎس اﻟﻠﻮﻧﻲ. اﻟﺘﻮاﻟﻲ
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وهﺬا % 69ﻟﻠﺨﻼﻳﺎ وﺟﺪ أن اﻟﻨﺴﺒﺔ ﻀﺨﻢ اﻟﻤﻟﻔﻴﺮوس ( ج)ﻟﻘﻴﺎس ﻣﻌﻴﺎر اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻣﻦ ﻧﻮع 
 . ﻳﻮﺿﺢ أن اﻟﻄﺮﻳﻘﺘﻴﻦ ﺗﻌﺘﺒﺮان ذات ﺣﺴﺎﺳﻴﺔ ﻋﺎﻟﻴﺔ ﻟﻘﻴﺎس ﻣﻌﻴﺎرﻳﺔ اﻷﺟﺴﺎم اﻟﻤﻀﺎدة ﻟﻠﻔﻴﺮوس
 ﻟﻠﺨﻼﻳﺎ ﻓﻲ آﻞ اﻟﻤﺠﻤﻮﻋﺎت ﻢ اﻟﻤﻀﺨﻳﺘﻀﺢ ﻣﻦ هﺬﻩ اﻟﺪراﺳﺔ أن اﻹﺻﺎﺑﺔ اﻟﻌﺎﻟﻴﺔ ﺑﺎﻟﻔﻴﺮوس
 . اﻟﺘﻲ ﺗﻢ دراﺳﺘﻬﺎ ﻗﺪ ﺗﺆدي إﻟﻰ رﻓﺾ اﻷﻋﻀﺎء ﺑﻌﺪ زراﻋﺘﻬﺎ
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CHAPTER ONE 
INTRODUCTION 
       The human CMV belong to herpesvirridae family. CMV naturally 
acquired infection has three categories; those acquired before birth 
(congenital) or at time of delivery (prental) or later in life (postnatal), 
(Baumoch et al: 1999). Many genetically different strains of CMV are 
circulating in human populations. These strains are sufficiently related 
antigenically and strain differences are probably not important 
determinants in human disease. CMV may be species- specific-cell type 
specific, most of which have a tropism for salivary gland and kidneys. 
(Baumoch et al: 1999) 
 Like all herpes viruses, CMV establishes life long latent infection 
and the virus can be shed intermittently from the pharynx & urine for 
months or years after primary infection. (Tony ,et al, 1993). Over 50% 
of the adult populations have a serological evidence of a latent infection 
with the virus, though infection is generally symptomless. An occult 
viraemia is readily demonstrated in many patients with acquired CMV 
infection or even in apparently normal individuals by isolation of the 
virus from white blood cells. Prolonged shedding of the virus after 
congenital or acquired CMV infection contributes to the ease of the virus 
transmission. (Barbara, 2000) 
CMV-Specific antibodies of IgM, IgG and IgA classes have all 
been detected; nonetheless, reactivation of latent infection occurs in the 
presence of humoral immunity. Infants may become infected though 
they possess high titer of maternal antibodies acquired transplacentally. 
Maternal antibodies seem to protect more against development of serious 
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disease in the infant rather than viral transmission. Cell-mediated 
immunity is depressed with primary CMV infection; it may take several 
months for cellular response to recover. This may contribute to 
persistence of the viral infection. The host immune responses 
presumably maintain Ab-CMV latent state in seropositive individuals 
(Raynor, 1993) 
CMV infections are wide-spread and usually asymptomatic. 
However, the incidence and spectrum of the disease in new born and 
immuno-comprmized host established, this virus as an important human 
pathogen.  
       Disseminated CMV infection can be obtained in children and adult 
with malignancies e.g. leukaemia and in patients treated with 
immunosuppresive agents after organ transplant. The possible sources of 
the virus include blood transfusion and in case of renal transplants, the 
latent virus in the graft itself. However, prolonged CMV infection of the 
kidney does not seem to be deleterious in normal persons, but it may 
contribute to renal dysfunction and rejection in patients receiving kidney 
transplant. (Lozzarotto et al., 1998). 
After renal transplantation virtually all sero-positive recipients 
shed viruses but most remain asymptomatic (Reactivation of latent 
virus). However, recipients of renal transplants undergoing primary 
infection are more likely to develop symptoms and graft rejection. 
Furthermore, post-transfusion syndrome occurs mostly after open heart 
surgery when a large volume of blood is used. The source of the virus in 
this case is leukocytes of a latently infected donor (Lozzarotto et al., 
1998). 
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It appears that CMV poses an important public health problem 
because of its high frequency of congenial and postnatal infection. 
Furthermore, the indirect effects of CMV infection on graft and patient 
survival have been increasingly recognized in recent years.                
              The present study was carried out to fulfill the following 
objectives: 
1. To study the prevalence of CMV IgM antibodies among renal 
transplant recipients, kidney donor candidates and blood 
donors using Enzyme Linked Immuno sorbent Assay (ELISA) 
and Immunochromatography (ICT). 
2. To estimate the extend of active CMV infection in the various 
groups using IgM ELISA.   
3. To prevent transmission of primary CMV infection as CMV 
negative transplant recipient population, represent high risk 
group for CMV infection that culminate in graft rejection. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 History of Cytomegalovirus: 
            The medical and public health impact of CMV results largely 
from its role as a leading cause of congenital infection. The history of the 
discovery of CMV is closely linked to early 20th century studies of the 
pathology of fetuses and newborns who died from a multisystem disease 
characterized by prominent central nervous system, hepatic and 
haematological abnormalities (Jesionck, 1904).  
 Cytomegalovirus (CMV) was first isolated from the salivary gland 
and kidney of two dying infant mice showing cytomegalic inclusion 
bodies (Smith, 1954). Two other laboratories isolated CMV at 
approximately the same time (Smith, 1954). Thus, CMV was initially 
called”salivary gland virus or salivary gland inclusion disease virus. 
Weller et al in 1960, proposed the use of the term cytomegalovirus. 
Klemola et al (1970) were first to described CMV mononucleosis, in 
previously healthy individuals. CMV was isolated from a renal 
transplant recipient as reported by Jawetz, et al. (1995). 
2.2 Classification:  
Cytomegalovirus is a DNA virus, which belongs to the subfamily 
beta–herpesvirinae of the family herpesviridae. Members of the 
subfamily beta–herpesvirinae tend to have a relatively restricted host 
range, long growth cycle and slow spread in cell culture (De John, et al., 
1998). Morphologically the herpesviruses are indistinguishable from one 
another. The complete virion is to 200 nm in diameter and icosaheral in 
shape and consists of an inner core, a capsid and an envelope (De John, 
et al., 1998). 
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2.3 Properties of CMV: 
 CMV is an enveloped virus. The inner core (genome) of the CMV 
virus is a 64 – nm linear double stranded DNA. The capsid is 110 nm in 
diameter and consists of 162 protein capsomers. The envelope contains 
lipoproteins and at least 33 structural proteins, some of which are 
glycoproteins. The glycoproteins determine the strain of CMV, and are 
used for cellular entry of the virus, and are the targets of virus– 
neutralizing antibodies (Baunoch et al., 1999). 
 CMV is a labile virus and is readily inactivated by lipid solvents, 
pH below 5, heat (37°C for 1 hr or 56°C for 30 min.), and ultraviolet 
light for 5 min. It can survive on environmental surfaces for several 
hours. CMV can be stored at 4°C for a few days without loss of 
infectivity. Storage at -70°C without loss of infectivity is possible for 
several months. CMV can be stored at -190°C (liquid nitrogen) 
indefinitely (Baunoch et al., 1999). 
2.4 The virus structure and genome organization:  
 Cytomegalovirus is an enveloped double stranded DNA virus, 
with icosahedral symmetry. The DNA has size of 150×106 kbp. The pre 
– envelope is glycoprotein in nature, and acts as receptor for Fc protein 
of immunoglobulins, (Fig. 1)(Jawetz, et al., 1995).   
 The vrion of human CMV consist of an icosahedral capsids 
encasing a 235kbp linear genome, surrounded by a tegument or matrix 
and enveloped in a lipid bilayer carrying a large number of virus 
encoded glycoproteins. 
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Fig. (1). Structure of Cytomegalovirus (Jawetz et al., 1995) 
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        The human CMV genome also exhibit a pattern of terminal and 
inverted repeats that varies in size depending on the virus strain and 
passage history (Wright et al., 1988). The only human CMV that has 
been completely sequenced is a laboratory-adopted strain AD169 var UK 
(Wright et al., 1988).    
2.5 CMV regulatory proteins:  
 The virus produce immediate–early (IE), and late CMV antigens. 
The IE antigens appear and remain present even in latent infection. IE 
antigen gene products direct production of both viral and cellular genes. 
Early antigens appear in the cytoplasm or membrane approximately 3 
hours after infection. Early antigen products direct viral DNA synthesis. 
Late antigens appear in the nucleus and cytoplasm within 6 to 24 hrs 
after infection. Late antigen gene products direct production of structural 
nucleocapsid proteins. IE antigens are virus–induced nonstructural 
proteins and appear before DNA synthesis. This is important because the 
mechanism of action of agents used for treatment of CMV is through 
interruption of DNA synthesis. Late antigens are virally encoded 
structural proteins, so their appearance is sensitive to the common 
antiviral agents, because of this, monitoring late antigen levels may be 
more relevant than monitoring IE levels when assessing response to 
therapy, (Bradshow et al., 1994).   
2.6 The virus structural proteins:      
     Purified virus particles of human CMV have been estimated to 
contain 30-40 polypeptides with molecular weight ranging in size from 
20 to over 300 kd. These proteins comprise the capsid, envelope and 
tegument proteins. The immunogenic proteins of human CMV are 
shown in Table (1). 
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2.6.1 The capsid proteins: 
The capsid is composed of seven proteins, all of which are 
homologous to those identified in HSV. These include the major capsid 
proteins (MCP) encoded by UL 86 and forms both hexons and pentons. 
The minor capsid protein(Mcp) encoded by UL 85,the minor capsid 
binding protein(mc-BP)encoded by UL 46,the smallest capsid protein 
(SCP) encoded by UL 48-5(also called UL 48/49),and three distinct 
assembilin protein (AP) related protein encoded by UL 80,UL 80a,and 
UL 80s associated with capsid (Baldick et al., 1997). 
2-6-2 The envelope proteins: 
        The vrion envelope carries two prominent herpes-virus-conserved 
glycoprotein complexes. One is composed of covalently-linked, 
proteolytically processed dimmers of glycoprotein B (gB) encoded by 
UL55 (Spaete et al., 1988) and the other is composed of the product of 
UL75,UL115 and UL74 genes gH, gL and gO glycoprotein respectively. 
These glycoprotein complexes play critical, but as yet incompletely 
understood,roles in entry that may be common to all herpesviruses. 
Glycoprotein B is one of the most highly conserved herpesviruses-
common protein (Chee et al., 1989). 
2-6-3 Tegument proteins: 
        Between the capsid shell and the envelope is the tegument that 
contains as many as 25 proteins many of which are phosphorylated as 
denoted by the prefix pp. The most prominent are ppUL83 (pp65), 
ppUL32 (PP150), ppUL99 (pp28), ppUL82 (pp71) and ppUL48 the huge 
tegument protein (Bradshow et al., 1994). Although several 
transcriptional transactivators (ppUL82, ppU-L69, pTRSI, pIRSI) have 
been localized in the tegument,the function of most tegument proteins 
 9
remain uncharacterized. Tegument proteins are conserved among 
betaherpesviruses but are not herpesvirus-common (Liu and Stinski, 
1992). 
2-7 Immunity to CMV:  
2-7-1 Cell-mediated immunity (CMI): 
        A central importance of CMI to the control of CMV infection is 
reinforced by the observation that individuals with deficiencies in 
cellular immunity exhibit the highest risk for CMV disease. Resistance 
to CMV infection depends on successful collaboration between the 
innate and adaptive immune responses. Both natural killer (NK) cells 
and cytotoxic T lymphocyte (CTL) whose presence correlates with 
protection from CMV disease (Boppana and Britt, 1996; Zanghellini et 
al., 1999), play prominent role in immune clearance. 
        In humans with naturally acquired CMV-infection, CD4 + helper T 
lymphocyte responses to multiple structural and nonstructural CMV 
protein have been demonstrated (Hengel et al., 1994). CTL responses to 
CMV was associated with clinical recovery from CMV disease (Quinnan 
et al., 1982).In human,CD8+ CTL responses to a number of CMV 
protein has been described in table (2). 
Beige mice, genetically deficient in NK cell, have increased 
susceptibility to murine CMV (Shellam et al., 1981). Depletion of NK 
cells from mice led to more serious infection after challenge (Bukowski 
et al., 1984). A case report of a patient with deficient NK cell responses 
and has sever infection by CMV and other herpesvirus produces clinical 
evidence for a role for NK cell in initial control of CMV infection in 
humans (Boppana and Britt, 1996). 
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Table (1):  Immunogenic proteins of human CMV                     
Application Immune response Location Name (ORF) 
Subunit vaccines 
and serological 
assay. 
Major target of 
neutralizing Ab 
Envelope (gB) gI(UL55) 
Therapeutic- 
human and        
serological assay 
Major target of 
neutralizing Ab. 
Envelope 
(gH) 
gI(UL75) 
Serological assay 
Non neutralizing 
Ab and CD8+ CTL
Tegument pp150(UL32) 
Serological assay 
Non neutralizing 
Ab. 
Tegument pp28(UL99) 
Serological assay 
Non neutralizing 
Ab. 
Matrix pp71(UL82) 
Serological assay 
Non neutralizing 
Ab. 
Non structural 
(NS) DNA 
binding. 
pp52(UL44) 
IE Ag detected in 
rapid culture 
assay (shell viar) 
Target of non 
neutralizing Ab 
and CTL. 
IE, NS, 
regulatory 
pp71(UL123) 
ORF: open reading frame, NS: nonstructural, IE: immediate early, CTL: 
cytotoxic T lymphocyte, hu-mab humanized monoclonal Ab. (From Pass, 
Field’s virology, 2001) 
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2-7-2 Humoral immunity: 
        Experimental and clinical evidence indicates that humoral immunity 
to CMV plays a key role in protecting the host from disease. The 
humoral immune response is critical in neonatal disease (Yeager et al., 
1981) and solid organ transplant setting (Syndman and Falagas, 1996) 
and it is less clearly important in other settings such as bone-marrow 
allografting. Abs to approximately two dozen of immunogenic CMV 
protein can be detected in sera of seropositive humans. The proteins to 
which immune human sera most consistently react are listed in table (2). 
Neutralizing antibody is directed principally against envelope 
glycoproteins Gb and Gh but also against other envelope glycoprotein 
(Britt, 1991).   
2.7.3 Immune Evasion and Piracy by CMV :  
 The CMV virus has developed a number of mechanisms to subvert 
host defenses. One of these is the ability to downregulate expression of 
major histocompatibility complex class 1 molecules (MHC I), which 
may allow evasion of and recognition by cytotoxic T lymphocytes, 
(Wiertz et al, 1997). Human CMV proteins also block transporter 
associated with antigen processing, retain MHC class 1 molecules in the 
endoplasmic reticulum, and recycle nascent class 1 heavy chains back to 
the cytosol, because MHC class 1 molecules, on cell surface inhibit 
natural killer cell cytotoxicity. CMV–infected cells express  
CMV gpUL18, a class 1 homologue that may inhibit natural killer 
cell cytotoxicity. Recently, another CMV antigen, gpUL40, has been 
shown to upregulate the nonclassical MHC class 1 molecule HLA–E 
which inhibits NK cells (Barbara, et al., 2000). 
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Table (2): Human CMV genes associated with evasion of NK cells, 
CD8+ CTL and CD4+ immune responses: 
Evasion mechanism CMV gene Host response 
Cell surface expression of  HlA- E 
which binds inhibitory receptors on 
NK cells 
UL40 NK cell killing 
Detention of MHC class I complexes 
with endoplasmic reticulum(ER) 
Retention of MHC classI heavy chains 
in to cytosol 
Export of MHC class I heavy chain 
from ER via Sec61 
Inhibition of TAP-mediated -
translocation into the ER 
Inhibition of presentation of 
72-kdIE antigen to CD8+ T cells 
Degradation of MHC class II 
preventing presentation of Ags to 
CD4+ T cells 
US3 
 
US11 
 
US2 
 
US6 
 
US83 
 
US2 
 
MHC-class I 
Ag presentation processing 
 
 
 
 
 
MHC class II presentation 
of Ag. 
From Hengel et al (1998) 
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 In addition to the mechanisms listed on table (2) CMV exhibit a 
number of other activities that could impede viral host defense. These 
include production of a viral IL–10 homologue. IL–10 blocks 
proinflammatory cytokine synthesis and suppresses the ability of 
macrophages to serve as antigen – presenting or co-stimulatory cells 
(Tony, 1993), binding and sequestration of β– chemokins (US27, UL28 
and UL33), competition with TNF receptor superfamily though a 
homologue (UL144), interference with apoptosis and protection from 
complement–mediated laysis (Lagenaur et al., 1994)       
2.8 Pathogenesis: 
        Although a number of host factors or clinical variables related to 
virulence of CMV infection have been identified, the contribution of 
specific viral genes and gene products in determing virulence of CMV 
infection are poorly understood. Nonetheless the role of the upper 
teguments protein pp71 (UL82) is considered a determinant of infectivity 
as it increases late gene expression and cell-to-cell spread of the virus 
(Baldik et al., 1997), the envelop glycoprotein(gB) has been also 
proposed as a determinant of virulence(Chau and Dennism, 1991).  
Primary infection typically starts with replication in mucosal 
epithelium.A systemic phase of the disease disseminates the virus in the 
host via a leucocytes –associated viraemia that may last for several 
months (Zanghellini et al., 1999). 
        Cell-mediated immunity (CMI) is depressed with primary CMV 
infection and it may take several months to recover. Although an initial 
persistant is often observed, clearance of a cute infection is the norm in 
all immunocompetent individuals (Pass et al., 1986) and it is corelated 
with a slow rise in CMI. 
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Most of CMV infections are subclinical, like all herpesvirus, 
CMV establishes life long latent infection and the virus can be shed in 
body fluids for months to years. 
        Pathogenesis of CMV disease is directly linked to the immune 
status of the host. Innate and adoptive immune mechanisms control acute 
virus infection, maintain latent infection and modulate virus during 
reactivation. However clearance mechanisms are subjected to a range of 
viral immunomodulation that both thwart the effect of the immune 
response and use the immune system to end that benefit the virus. CMV 
infection directly perturbs immunofunction, leaving the host open to 
disease (Belgrami et al., 1999). 
2-9 Latent infection:   
          Evidence has accumulated that Human CMV remains latent in 
lineage-committed myeloid cells, including progenitor cells that give rise 
to granulocytes, macrophage and dendritic cells and possibly endothelial 
cells. (Sinzger and Jahn, 1996). Viral DNA is present in mononuclear 
cells derived from peripheral blood or bone marrow of healthy sero-
postive individuals (Bevan et al., 1991), but infectious virus is not 
present. Viral gene expression in latently infected progenitor cells is 
restricted to latency associated transcripts that have been observed in 
both natural and experimental infection in cells with surface molecule 
CD33 (Hahn et al., 1998). The pattern of latent gene expression change 
as these cells mature into monocytes or dentritic cells (Hahn et al., 1998) 
and may become productive as a result of differentiation under 
proinflammatory conditions. Differentiation of primary peripheral blood 
monocytes-derived macrophages with presence of activated T cells 
promotes cell differentiation and support reactivation of latent virus 
(Soderberg-Naucher and Nelson, 1997). 
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2-10 Reactivation CMV infection: 
         Reactivation is believed to be more important than primary 
infection as a virus–causing disease in the immunocompromized host 
and is thought to occur as a result of at least three collaborating events:               
a\ Cytokine stimulation of latently infected cells causing 
differentiation into a permissive cell type that supports viral 
replication (Hahn et al., 1998). 
b\ Viral amplification caused by reduced immune surveillance 
that leads to wide spread systemic infection with readily 
detectable viraemia (Farrel et al., 1999) and virus in many 
tissues. 
c\ Disease state develops as a result of poorly understood 
collaboration of immune-organ and virus species determinants. 
        The three stages of reactivation help illuminate on important 
interplay of the immune response in reactivation and pathogenesis 
(Farrel et al., 1999). Immunocompromized individuals who support 
persistent infection or who frequently reactivate and shed viruses may be 
predisposed to more rapid amplification and clinical disease  because the 
first event is unnecessary. Most clinical manifestations of reactivation 
results from second events, after virus replication reaches readily 
detectable levels. The consistency with which CMV reaches high 
systemic levels prior to and the absence of disease is the basis of 
preemptive antiviral or adoptive CMV specific CTL therapies (Riddel 
and Greenberg, 1997), as well as being the basis for the dramatic 
reduction in incidence of CMV retinitis and gastroenteritis resulting from 
immune reconstitution that follows highly active retroviral therapy in 
AIDS patients (Doniger et al., 1999). 
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        The earliest event in reactivation (the first event) is a facinnating 
area of virus biology. Cytokine-mediated differentiation of peripheral 
blood monocytes into macrophages under strongly proinflammatory 
conditions is undoubtedly key to this process (Meier and Stinski, 1996). 
          Experimentally infected myeloid cells reactivate latent virus when 
cultured in the presence of IFNγ or TNFά which are part of natural 
inflammatory response (Hahn et al., 1998), but this signal is insufficient 
to reactivate naturally infected bone marrow derived cells. Naturally 
infected peripheral blood monocytes-derived macrophages require the 
presence of allogeneically stimulated T cells to reactivate latent virus 
and IFNγ contributes important signals to this process (Snydman and 
Falagas, 1996).The accumulated data suggest that latency is preserved as 
most monocytes differentiate and that specific proinflammatory signals 
to be delivered to latently infected cells for reactivation to ensue 
(Soderberg-Naucher and Nelson 1999). 
Proinflammatory signals are likely to be generated during allograft 
rejection, reinforcing a clear connection between inflammatory signals, 
allogenic rejection and reactivation. A low level of reactivation and 
replication of CMV itself may have an amplifying effect on 
inflammation that derives further reactivation. 
2.11 Clinical Features of CMV spectrum of disease: 
2-11-1 CMV mononucleosis: 
        Mononucleosis due to CMV is very similar in clinical manifestation 
to the more common Epstein Barr virus (EBV)-induced disease 
(Klemola et al., 1970). It has been estimated that CMV is responsible for 
20%t to 50% of heterophil-negative mononucleosis and that it accounts 
for approximately 8% of all cases of mononucleosis (Klemola et al., 
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1970). Pneumonia, retinitis, and gastrointestinal infection are the 
common manifestation of disease, (Baunoch, et al., 1999).  
There are two forms of disease caused by CMV which are 
determined by the route of infection whether acquired or congenital.    
2-11-2 Congenital form: 
      When the congenital form is clinically evident, it’s typically 
manifested by sings and symptoms that indicate in utero involvement of 
multiple organ system (Boppana et al 1992). About 0.2% to 2.4% of 
infants, who are congenitally infected with CMV, develop symptoms and 
signs, 90 to 95% are asymptomatic at birth but may have low birth 
weight compared with non-infected neonates. Congenital CMV infection 
is an important medical and public health problem because it causes 
damage in the CNS and organs of perception. Symptomatic babies, 
present with jaundice, hepatosplenomegly, chronic lung disease, growth 
retardation, ophthalmologic abnormalities and deafness (Barbara, et al., 
2000). 
2-11-3 Community Acquired form: 
 This form results following infection of individuals after birth. 
Virus being acquired by droplet infection or blood transfusion. Only 
cellular blood products (whole blood, red cells, platelets and leukocytes) 
are capable of transmitting CMV. The dose of infected leukocytes 
transfused is an important risk factor, as evidenced by the increasing risk 
of seroconversion with increasing number of units of blood transfused. 
Transmission is lower with stored blood products than fresh blood 
products due to the breakdown of leukocytes (Brabara, et al, 2000). 
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Table (3) Rates of CMV infection and disease in Kidney and liver 
transport patients: 
Liver Kidney 
Disease% Infection% Disease% Infection% 
Type of 
infection 
Pretransplant 
serostatus of 
donor/recipient 
23 66 19 51 
Reactivation 
or 
reinfection 
+/+ 
61 77 50 67 Primmary +/- 
10 49 12 59 Reactivation -/+ 
10 10 0 0 
Primary,not 
from graft 
-/- 
From Pass (Field virology 2001)   
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 The signs and symptoms include fever, low white cells count, 
muscle weakness, arthritis, fatigue, mental confusion, shortness of 
breath, blurring of vision, bloody stool, nausea, vomiting, diarrhea, 
malaise, weight loss and facial edema, pharyngitis, lymphodenopathy 
and appearance of a typical lymphocytes in peripheral blood films 
atypical, (Baunoch, et al., 1999).  
2-12 CMV infection in immunocompromized host: 
        CMV is one of the most common and diffcult of the opportunistic 
pathogens that complicate the case of immunocompromized patients. 
Infection is common because it can occur by a/ Reactivation of latent 
virus, b/ Reinfection with new strains in patients who have had post 
infection, c/ Primary infection. 
Procedures that are part of the patient's care, such as transfusion or 
organ transplant, can transmit CMV at a time when the patient is 
maximally immunosuppresed. The severity of CMV infection roughly 
parallels the degree of immunosuppresion. Sever infections are seen in 
recipient of allogenic bone marrow transplant and in patients with 
acquired immunodeficiency disease (AIDS) with very low CD4+cell 
counts. CMV disease is also seen in solid organ transplant patients, in 
patients receiving immunosuppressive chemotherapy for cancer or 
collagen vascular disease and in congenital immunodeficiency (Pass, 
2001).   
2.13 Solid organ transplantation vs. CMV infection: 
Symptomatic CMV infection occurs in 20 to 60% of all transplant 
recipients and is a significant cause of increased morbidity and morality 
in this population. The incidence may be somewhat lower in kidney 
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transplant recipients who do not receive antilymphocytes therapy, high – 
does mycophenolate, or the potent combination of mycophenolate and 
tacrolimus without adequate antiviral prophylaxis. This wide range in the 
reported incidence of infection and disease result from the varying 
intensities of immunosuppression used and the frequency and method 
used to detect CMV infection, (Lozzarotto, et al., 1998). Historically, 
attention has focused mainly on avoiding CMV infection in the CMV 
Donor (+)/Recipient (-) group because the negative recipent group has 
been at greatest risk for severe primary infection during the first 3 
months after transplantation. However, the indirect effects of CMV 
infection on graft and patient survival have been increasingly recognized 
in recent years. Analysis of data showed that even in compatible 
transplant, the survival of recipient did not exceed 3 years when either 
the  donors  or  recipient was positive for CMV antibodies (Lozzarotto, 
et al, 1998).  
Subclinical CMV in transplant recipient may also mimic and or 
predispose to late acute rejection. Late subclinical infections are 
common and associated with relatively rapid graft loss, as reported by 
Van der Bij, et al. (1988) (Table 3).  
2.14 Mechanisms that lead to kidney transplant rejection: 
 CMV has been associated with both atherosclerosis and chronic 
rejection, and the two most common causes of late graft loss are 
cardiovascular death and chronic rejection. Chronic rejection is also 
known as a chronic allograft nephropathy and is characterized by 
myointimal thickening, which is a form of atherosclerosis. Latent CMV 
infection has been associated with a markedly increased rate of estenosis 
(120% higher) after coronary angioplasty in non – transplant seropositive 
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individuals compared with seropositive individuals. Furthermore, the 
histologic lesion of coronary estenosis is diffuse atherosclerosis 
characterized by myointimal hyperplasia resembling chronic rejection. 
CMV is believed to affect Tumour suppress protein (P53)(Marie, et al., 
1993). However, more recent evidence suggests that the myointimal 
increase is not from proliferation but rather from migration of smooth 
muscle cells (SMC) mediated by virally encoded chemokine receptors 
that require tyrosine kinase before expressions, (Gerna, et al., 1998). 
SMC migration could be blocked by tyrosine kinase inhibitors and this is 
suggest another potential therapeutic strategy. Finally, human CMV 
infection may also cause atheroscerlosis and chronic rejection by 
increasing oxoidized low – density lipoprotein uptake by vascular SMC, 
(Blok, et al., 1999). This process is mediated by the IE gene IE72 and 
does not require viral replication, which may explain why angioplasty 
patients who were infected latently with CMV have higher rates of 
estenosis after angioplasty. 
 CMV has been associated with several other vascular injuries that 
may explain why the D+/R+ group has the worst overall survival. One 
such vascular injury associated with CMV is transplant glomerulopathy. 
However, the frequency and clinical significance of this lesion are 
uncertain, (Gerna, et al., 1999). The lesion of the hemolytic uremic 
syndrome/thrombotic microangiopathy is one of the more common 
vascular pathologies associated with CMV and may be confused with or 
present with cyclosporine or tacrolimus toxicity, (Eggers, et al., 1998 
and Nigro et al., 1999). CMV–associated hemolytic uremic syndrome/ 
thrombotic microangiopathy may respond to Ig infusion, (Nigro, et al., 
1999). 
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The IE gene product up regulates transcription and expression of 
interleukin – 2 (IL-2) and the IL-2 receptor (Baunoch; et al 1999). The 
CMV IE gene also prevent the inhibitory effect of cyclosporine on IL – 2 
transcription (Consten, et al., 1993). It may do this in part by sustained 
nuclear containing nuclear factor– KB enhancer sequences. The IE and 
early antigen gene products also upregulates adhesion molecules such as 
intracellular adhesion molecule– 1(ICAM-1) and lymphocyte functional 
molecule–1(LFA-1) and lymphocyte functional antigen–3(ICAM-3). 
Upregulation is not blocked but actually enhanced with treatment with 
ganciclovir and foscarnet (Mijanovic, 1992). Thus, CMV infection can 
initiate endothelial activation and rejection despite effective treatment 
with ganciclovir, foscarnet, or cidofovir.  
2.15 Laboratory Diagnosis of CMV infection:  
 There are several methods for diagnosing CMV. Until recently, 
the available techniques for diagnosing CMV were limited to histologic 
identification of CMV inclusion bodies, viral culture, and serology. 
These techniques are costy and not completely sensitive and the time 
from primary infection or reactivation to detection of CMV is protracted, 
allowing the progression of undetected and untreated disease, (Turgeon, 
et al., 1998). In addition, transplant recipients may fail to produce an 
antibody response despite other evidence for viremia, making the 
developed new techniques preferable to serology for the detection and 
monitoring of the virus. These techniques include shell vial culture, pp65 
antigenemia assay, PCR, and the hybrid–capture RNA-DNA 
hybridization assay, which has recently received Food Developed 
Administration (FDA) clearance for the qualitative detection of CMV-
DNA. Other more recently developed techniques are the branched DNA 
assay and the nucleic acid sequence–based amplification, which 
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amplifies large quantities of RNA, (Turgeon, et al., 1998). However 
clinical utility of both tests in renal transplantation remains to be 
determined. The CMV-PCR uses DNA that does not deteriorate and is 
not diminished with storage, (Turgeon, et al., 1998). 
2.15.1 Culture methods:  
        Although a variety of cell culture systems are permissive, human 
CMV is propagated best in fibroblasts of human origin. The growth of 
human CMV is characterized by a relatively prolonged replication cycle 
and distinctive focal cytopathic effect (CPE) with cell enlargement and 
rounding. Human foreskin fibroblasts and human embryonic fibroblasts 
W1-38 and MRC5 are commonly used for propagation and early 
cytoplasmic inclusions are visible by five hour postinfection (Albrecht et 
al., 1998). 
        Nucleoli become distinctly defined in the centrally placed nucleus 
by 24 hours. The characteristic eosinophilic perinuclear inclusion 
appears and with progression of the replication cycle, become more 
distinctly defined. By 48 to 72 hours postinfection, CPE is well 
developed with prominent cell enlargement, a basophilic perinuclear 
inclusion (Fig 2). Progeny virus accumulates in the cytoplasm of infected 
cells and about 96 to 120 hours postinfection, infectious virus appears in 
tissue culture fluids-inoculum size cell culture lineage, and CMV strain 
influence the appearance of CPE in tissue culture monolayer (Albrech et 
al., 1980). Distinct patterns of CPE are expressed by the two prototypic 
laboratory-adopted strains of humans CMV, AD169 and Davis (Albrech 
et al., 1980). Davis strain CPE is characterized by rounded cells with 
eccentric, kidney shaped nucleus. Fibroblast infected by the AD169 
strain recover from early cell rounding and retain their enlarged shape. In 
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addition nuclear morphology is less distorted and perinculear inclusion 
are less distinct. Clinical isolates usually exhibit the Davis-Type CPE.  
2.15-1-1 Rapid shell vial culture:  
 Shell vial culture differ from conventional cell culture techniques, 
5 ml of EDTA–treated blood is allowed to sediment by gravity and the 
leukocyte – rich plasma is removed and centrifuged. The pellet is 
washed twice with Eagles minimal essential media, and then is 
resuspended in 2 ml of Eagles minimal essential medium with 10% fetal 
bovine serum. However conventional cell culture with human embryonic 
lung fibroblast cell (HEL299 American Type Culture Collection), is 
inoculated with 1 ml of cell suspension conventional cell are maintained 
for 4 – weeks. Three shell vials prepared weekly with MRC-5 cell are 
inoculated with 0.3 ml of cell suspension and centrifuged at 700 g for 40 
minutes, at 20 to 30°C.  
 Cover slips from shell vial are fixed, stained with fluorescein 
isothiocyanate – labeled CMV monoclonal antibody and examined after 
16 to 20 hours. The third shell vial is examined after 48 hours, (Tony, et 
al., 1993).  
2.15-2 Serology:  
 Detection of the IgM and IgG antibody response to CMV may be 
delayed due to the fact that the antibody response appears 10 to 14 days 
after the start of active infection. The IgG class of antibody indicates 
previous infection. Positive IgM class of antibody is an indicator of a 
recent or current infection, (Barbara, et al., 2000).   
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2.15-2-1 Enzyme linked immunosorbent assay (ELISA):  
 ELISA is the most commonly available serologic test for 
measuring antibody to CMV. The result can be used to determine 
whether it is due to acute infection, previous infection, or passively 
acquired maternal antibody in an infant. ELISA technique for CMV – 
specific IgM may give false positive results unless steps are taken to 
remove rheumatoid factor.   
 Enzyme linked immunoassay is proved to be a useful technique 
when recombinant antigens are used to differentiate between primary 
and secondary or post CMV infection in pregnancy. It was found that 
IgM response to recombinant proteins and pp150 in primarily infected 
women varies. Predominant IgG response to p52 was observed in early 
sera less than 4 weeks after seroconversion, whereas IgG response to 
recombinant proteins pp150 was delayed and appeared 2-7 weeks later. 
On the other hand, women with secondary and those with post primary 
infection had IgG antibodies to pp150, (Daiminger, et al., 1998).  
2.15-2-2 Immunochromatography Technique (ICT):  
 The CMV (ICT) or one step test device (serum/plasma) is a rapid 
immunoassay for the qualitative detection, of antibodies to CMV (Choo 
et al., 1989). ICT are modeled after the home pregnancy tests used by 
women in many countries. They differ from usual systems for measuring 
antigen – antibody reactions in that the specimen from the human subject 
is made to flow through a filter after which it is immobilized in a 
membrane at a site where antigen (or antibody) in the specimen comes 
into contact with the test antibody (or antigen) already present in the 
membrane. All controls are included in the membrane as well, and 
results are seen as colored bands or lines, as one of the test reagents is 
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conjugated to colloidal gold or chromogenic substance (Murphy et al., 
1999).   
2.15-2-3 Immunobloting:  
 The immunoblot for detection of CMV – specific IgM in human 
sera is a new diagnostic technique. Four viral proteins (vp150, vp82, 
vp65 and vp28) and 4 recombinant proteins (rp150, jp130, jpp52 and 
rp38) were purified from Eschirichia coli. These antigens were 
individually loaded into nitrocellulose strips with specific conjugate for 
the detection of CMV specific IgM. The immunoblot test combine with 
high sensitivity and specificity, (Lozzarotto, et al., 1998). 
2.15-2-4 Microneutralization assay: 
 Neutralization has been used to differentiate between acute 
primary and recurrent cytomegalovirus infection. It was found that 
neutralizing antibodies first appear approximately 15 days after acute 
infection, (Eggerts, et al., 1998).   
2-15-3 Polymerase chain reaction (PCR):  
 PCR is amplification of viral DNA or RNA. The PCR provides 
sensitive detection of CMV virus and closely correlate with antigenemia, 
but the specificity and the positive predictive value is lower than a 
standardized antigenemia assay. In another study, it has been reported 
that the use of polymerase chain in blood donor population samples 
showed sensitivity reaching up to 5 fg/microliter (Wong et al., 1997).  
2-15-4 Antigenaemia assay:  
 Antigenaemia assay means detection of CMV antigens in 
peripheral blood leukocytes. It is usually done for bone marrow transplant 
patients as well as in AIDS patient. In antigenemia assay technique, 
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monoclonal antibodies to CMV lower matrix protein (pp65), labelled 
with immunoperoxidase have been used (Van der Bij, et al., 1988). PMN 
are the suitable source for preparation of cytospot that is used for 
antigenamia assay which was proved to be more specific than virus 
isolation, (Marie  et al., 1993).  
2-15-5 Nucleic acid sequence based amplification (NASBA):  
 The nucleic acid sequence based amplification technique has been 
used in early detection of CMV infection after kidney transplantation 
because the viral immediate early (IE) messenger RNA is expressed in 
blood leukocyte. This technique proved to be the most sensitive assay 
that detected the onset of both primary and secondary cytomegalovirus 
infection that enabled the start of effective antiviral therapy in patients at 
risk, (Blok, et al., 1999). The same technique was applied to 
cytomegalovirus pp67 in bone marrow transplant recipients. It was found 
that the NASBA detect CMV infection before quantitization of viremia 
by PCR did, the sensitivity of NASBA reached 100% while it is 
specificity 68.9%, (Gerna, et al., 1999).  
2.15-6 Cytology assay:  
Urine cytology is a simple rapid, cost effective and accurate 
protocol for detection of cytological change in both benign and 
malignant condition, (Tony, 1993).  
Cytomegalovirus infected cells in routinely prepared blood films 
of immunosuppressed patients were found to be 50-60 micron in 
diameter with granular eosinophilic cytoplasmic inclusion and eccentric 
enlarged nucleus, as if derived from endothelial origin. This unique 
appearance of these cells with Wright and Giemsia may lead to their 
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possible misidentification as malignant or other cells, (Pooley, et al., 
1999).  
2.16 Treatment and control of cytomegalovirus:  
2.16.1 Treatment: 
 Ganciclovir nucleoside structurally related to Acyclovir has been 
used successfully to treat life threatening cytomegalovirus infections in 
immunosuppressed patients. The severity of cytomegalovirus retinitis, 
esophagitis and colitis is reduced by Ganciclovir which also reduces the 
incidence of cytomegalovirus pneumonia in bone marrow allograft 
recipients. Acyclovir, Vidarabine and interferon have also been used, 
(Jawetz, et al., 1995). Oral acyclovir is a superior agent providing 
prophylaxis for recipient of seropositive kidney donor, (Flenchner, et al., 
1998). 
In bone marrow transplantation in preemptive antiviral therapy, 
patients were given Gancicvir for 3-4 months when infection is first 
identified after transplantations, while in prophylaxis Ganciclovir is 
given to all patients at risks of human CMV disease 3-4 months post 
transplantation, (Stocchi, et al., 1999).  
2.16.2 Control:  
 Specific control measures are not available for prevention of 
cytomegalovirus spread but screening of transplant donors, recipients as 
well as blood donors for cytomegalovirus antibody may help in 
preventing some transmission of primary cytomegalovirus.  
Administration of human IgG prepared from plasma pools 
obtained from healthy persons with high titers of cytomegalovirus 
antibodies effectively decreases the incidence of CMV infection in 
transplant recipients. It has been reported that when CMV 
immunoglobulin was administrated to pregnant women with primary 
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cytomegalovirus infection and placenta involvement of twin fetus, 
inhibition of viral activity due to high titer of cytomegalovirus 
neutralizing  antibodies  and cell–mediated immunity improved, (Nigro 
et al., 1999). The administration of CMV hyper-immunoglobulin 
intraperitonealy proved a useful therapy of congenital CMV infection, 
(Negishi, et al, 1998). In renal and liver transplant recipients, receiving 
anti–lymphocyte intravenously and oral Ganciclovir for 3-4 months 
provide  virtually  complete protection against CMV disease, (Turgeon, 
et al., (1998).  
 A live-attenuated cytomegalovirus vaccine has been developed by 
repeated passage in human cells and has some preliminary success in 
clinical trials. However, the use of live cytomegalovirus vaccine remains 
controversial because of safety concerns. Another approach to 
immunization involves purified cytomegalovirus polypeptides that 
induce neutralizing antibodies, (Jawetz, et al., 1995).  
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CHAPTER THREE 
MATERIAL AND METHOD 
3.1 Study Design: 
 This is study is desired to determine the prevalence of CMV 
antibodies among blood donor and renal pretransplant recipients and 
kidney donors in Ahmed Gasim cardiac surgery & renal transplant 
centre. 
3-2 Study Area: 
 The study is conducted in Ahmed Gasim cardiac surgery & renal 
transplant centre, between January to December 2005 
 Ahmed Gasim cardiac surgery & renal transplant centre is located 
in Khartoum North. It is one of the main centers for cardiac surgery and 
renal transplantation. 
3-3 Study Population: 
      All patients waiting for kidney transplant, kidney candidate donors as 
well as blood donors attended the referred clinic in Ahmed Gasim Centre 
were included. Within the specified period, the total number of subjects 
initially using ELISA alone studied was 350. This number included the 
following groups: 
(1)  Group (1) 100 renal transplants patients (Kidney recipient). 
(2)  Group (2) 100 Kidney donors. 
(3)   Group (3) 150 Blood donors. 
Additional groups were included and the prevalence of 
CMV IgG antibodies were detected by Immunochromatography 
(ICT). These groups include: 
Group (4) 40 Kidney candidate recipients.  
Group (5) 40 Kidney candidate donors.  
Group (6) 80 Blood donors.  
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  The age of persons in the various group varied from 11 to 
60 years. 
3.4 Collection of blood:  
      Blood samples (510) were collected from various groups and sera 
was separated. Serum samples were labeled and kept in the refrigerator 
for up to seven days or kept frozen at -20C until used.      
3-5 Indirect ELISA for the Detection of CMV IgG and IgM 
antibodies: 
3-5-1 ELISA kits: 
The ELISA kits were purchased from Biokit, A.S. Spain and supplied 
as follows: 
1. Micro titer plate 12 x 8 wells coated with CMV recombinant 
antigens. 
2. Concentrated conjugate for IgG ELISA which is rabbit anti-
human IgG anti- Fc conjugated with peroxides containing red 
dye preservatives and protein stabilizers. To be diluted   1/51 
with the conjugate diluents before use (1.5µL). Like-wise 
concentrate conjugate for IgM ELISA, rabbit antihuman IgM 
anti- Fc, was also supplied. 
3. Conjugate dilluent. Consists of Tris buffer containing a yellow 
dye, additives and preservatives (70µL). 
4. Sample diluent. Tris buffer with protein stabilizers and sodium 
azides as preservative (120µL). 
5. Concentrated washing solution (500µL) which is phosphate 
buffer containing 1% tween 20 and 0.01% thimerosal.  
6. Substrate solution which is citrate-acetate buffer containing 
hydrogen peroxide (14µL). 
7. Chromogen which is 3, 31, 5, 51- tetramethyl benzidine (TMB) 
dissolved in dimethyl sulphoxide (DMSO).  
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8. Positive control which is diluted heat inactivated human serum 
containing antibodies to CMV containing sodium azide as 
preservative and a green dye (5µL). 
9. Negative control which is diluted human serum negative for 
anti-CMV. Contains sodium azide as preservative and a yellow 
dye. 
10. Stopping solution which is 1N sulphuric acid. 
11. Adhesive seals to cover plate during incubation. 
12. 12-Resealable bag for storage of unused strips of microtitre 
plate (MTP) 
3-5-2 Other materials not included in the kit: 
1. Distilled or deionized water. 
2. Multichannel pipette and micropipettes. 
3. Automated wash system. 
4. Microplate reader with 450 nm filter. 
5. Incubater with high relative humidity, at 37oC. 
3-6 Storage of ELISA kits: 
All kits components were stored at 2-8oC. The bag containing the 
microtiter plate should be brought to room temperature before opening to 
avoid condensation in the wells. Unused strips of (MTP) should be 
stored between 2-8oC tightly sealed in the plastic bag provided with the 
silica gel bag inside. The washing solution once diluted is stored 
between 2-8oC. The diluted conjugate is stable for 15 days at 2-8oC. The 
chromogen was stored protected from light and TMB solution was 
prepared according to the manufacture instructions.  
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3-7 Test procedure: 
3-7-1 Preparation of reagents: 
 Reagents were allowed to reach room temperature (20-25oC) 
before running the assay. All liquid reagents were mixed before use. The 
concentrated washing solution is diluted (1/10) with distlled water. The 
concentrated conjugate is diluted (1/51) with the conjugate diluent. All 
dilutions were made according to the manufacture instructions. 
3-7-2 Assay procedure for IgG and IgM antibodies:   
Six wells were reserved: one blank, three negative controls and 
two positive controls, each filled with 200µL of the appropriate serum 
control. Two hundred µL of sample diluent and 10 µL of each sample 
were distributed to the designated wells. The plates were covered with 
the adhesive seals, mixed gently and incubated for 1 hour at 37oC. There 
after the adhesive plate covers were removed and the content was 
discarded by aspiration and each well was filled approximately with 300 
µL diluted washing solution. This process was repeated five more times. 
After the last washing the microplates were blotted on absorbent tissue to 
remove any excess liquid from the wells. Then 100 µL of diluted 
conjugate anti IgG for IgG assay and anti IgM for IgM assay were 
transferred into each well of the microplates, except the blank. The plates 
were covered again with the adhesive seals and incubated for 30 minutes 
at 37oC.  
The adhesive plate covers were removed and discarded. The 
plate’s contents were aspired and washed once six times. Then 100µL of 
substrate-TMB solution were added to each well. All plates were 
incubated uncovered for 30 minutes at room temperature. The reaction 
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was stopped by adding 100µL of stopping solution in the same sequence 
and time intervals as for the substrate-TMB addition. The 
spectrophotometer was blanked at 450nm with the blank well read the 
absorbence of each well within 30 minutes. 
3-7-3 Reading of the test: 
For the validity of the assay the accomplishment of the following 
point is required: 
a- Negative control means (NCx): Absorbence of individual 
negative control values must be less than or equal to 0.200 OD. 
b- Positive control mean (PCx): It must be equal or greater than 
0.800 OD. 
c- The presence or absence of anti-CMV antibodies in the samples 
analyzed was determined by relating the absorbence value of 
each sample to the cut-off value of the technique. This value is 
the mean value obtained from the negative control plus 0.300 
OD. 
Cut-off = mean of NC + 0.300 OD. 
3-8 Interpretation of the test: 
If the test value of a serum was above the calculated cut-off value, 
the test serum was considered positive and if the test value is lower than 
the cut-off value, the sample is considered negative for the presence of 
CMV-antibodies. However, sera having test values equal to the cut-off 
value, these sera were retested in duplicates and if one duplicate has a 
value above the cut-off value the test was considered positive even if the 
other duplicate value was below the cut-off value. 
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3.9. Immunochromatography technique for the detection of CMV 
IgG antibodies:  
3.9.1. Materials provided:  
a) Test devices.  
b) Disposable specimen droppers.  
c) Buffer.  
3.9.2. Materials required but not provided:  
a) Specimen collection containers.  
b) Pipette and disposal tips.  
c) Centrifuge.  
d) Stop watch.   
3.9.3. Storage and stability: 
The kits were stored at room temperature or refrigerated (4° C). 
The test devices were kept in the sealed pouch until use. The expiratory 
date was observed.  
3.9.4. Test procedure:  
 Specimens were allowed to reach room temperature (20 – 25° C) 
before running the test. Frozen specimens were completely thawed and 
mixed well prior to testing. Freezing and thawing were avoided. Then 
the test device and buffer were allowed to equilibrate at the room 
temperature. We added a drop of specimen in device and two drops of 
buffer, then read the positive with two bands of control and test but the 
negative result give one band of control.     
 37
CHAPTER FOUR 
RESULTS 
       All samples of group 1, 2 and 3 were tested for the presence of 
CMV antibodies of IgM and IgG isotypes using indirect ELISA. 
Additionally we used ICT for the detection of CMV IgG antibodies in 
group 4, 5 and 6. The results of the various groups are shown below. 
4.1 Group (1 and 4) Kidney candidate recipients. 
      In this group 96% of the patients have CMV IgG antibodies using 
ELISA and 92.5% by using ICT (table 10 and 13) and only 10% of 
group (1)  have IgM antibodies as determined by ELISA and shown in 
tables (4 & 5) and figures (3 & 4). 
4.2 Group (2 and 5) Kidney candidate donors. 
      In this group 92% of samples tested have IgG antibodies using 
ELISA and 87.5% by using ICT (table 10 and 13). However, 17% of 
group (2) have IgM antibodies as determined by ELISA and shown in 
tables (6 & 7) and figures (5 & 6). 
4.3 Group (3 and 6) Healthy blood donors. 
      In this group 84% of the patients have IgG antibodies using ELISA 
and 82.5% by using ICT (table 10 and 13). However, 22% of group (3) 
have IgM antibodies as determined by ELISA and shown in tables (8 & 
9) and figures (7 & 8). 
     The prevalence of IgG antibodies in the total population studied by 
ELISA was 89% (table 10) and that of IgM antibodies was 17% (table 
11), whereas, the prevalence of CMV IgG antibodies in the total groups 
studied by ICT was 85% as described in table (13). The correlation 
between the two assay system for IgG antibodies was found to be 96%. 
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Table (4): The prevalence of CMV IgG in Kidney Recipient group (1) 
according to age 
Age of group/years NO  tested NO of + ve % 
< 10 - - 0 % 
11-20 18 18 100 % 
21-30 22 20 91 % 
31-40 34 32 95 % 
41-50 20 20 100% 
51-60 6 6 100 % 
 100 96 96 % 
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Figure (3): The prevalence of CMV IgG in Kidney 
Recipient group (1) according to age 
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Table (5): The prevalence of CMV IgM in Kidney Recipient group (1) 
according to age 
Age of group/years NO  tested NO of + ve % 
< 10 - - 0 % 
11-20 18 4 22.2 % 
21-30 22 2 9 % 
31-40 34 3 8.8 % 
41-50 20 1 5 % 
51-60 6 0 0 % 
 100 10 10 % 
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Figure (4): The prevalence of CMV IgM in Kidney 
Recipient group (1) according to age 
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Table (6): The prevalence of CMV IgG in Kidney donors group (2) 
according to age 
Age of group/years NO  tested NO of + ve % 
11-20 17 15 88 % 
21-30 46 45 97 % 
31-40 34 29 85 % 
41-50 3 3 100 % 
Total 100 92 92 % 
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Figure (5): The prevalence of CMV IgG in Kidney 
donors group (2)according to age 
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Table (7): The prevalence of CMV IgM in Kidney donors group (2) 
according to age 
Age of group/years NO tested NO of + ve % 
11-20 17 3 17.6 % 
21-30 46 6 13 % 
31-40 34 8 235 % 
41-50 3 0 0 % 
Total 100 17 17 % 
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Figure (6): The prevalence of CMV IgM in Kidney 
donors group (2)according to age 
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Table (8): The prevalence of CMV IgG in Blood donors group (3) 
according to age 
Age of group/years NO  tested NO of + ve % 
> 20 14 12 85.7 % 
21-30 90 73 81.1 % 
31-40 40 35 87.5 % 
> 41 6 6 100 % 
Total 150 126 84 % 
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Figure (7): The prevalence of CMV IgG in Blood 
donors group (3) according to age 
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Table (9): The prevalence of CMV IgM in Blood donors group (3) 
according to age 
Age of group/years NO  tested NO of + ve % 
> 20 14 5 35.7 % 
21-30 90 20 22.2 % 
31-40 40 8 20 % 
> 41 6 0 0 % 
Total 150 33 22 % 
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Figure (8): The prevalence of CMV IgM in Blood 
donors group (3) according to age 
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Table (10) Prevalence of CMV IgG in various groups studied by ELISA 
Studied groups NO tested NO of + ve % 
Kidney Recipient 100 96 96 % 
Kidney donors 100 92 92 % 
Blood donors 150 126 84 % 
Total 350 314 89 % 
 
 
 
Table (11) prevalence of CMV IgM in various groups studied by ELISA 
Studied groups NO  tested NO of + ve % 
Kidney Recipient 100 10 10 % 
Kidney donors 100 17 17 % 
Blood donors 150 33 22 % 
Total 350 60 17 % 
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Table (12): Range of optical density of CMV positive samples in various 
groups 
Studied groups 
OD 
Kidney recipient Kidney donors Blood donors 
OD (IgG) 0.8 ــــ 2.2 0.8 ــــ 2.0 0.8 ــــ 2.1 
OD (IgM) 0.8 ــــ 1.3 0.8 ــــ 1.83 0.8 ــــ 1.85 
 
 
 
Table (13): Prevalence of CMV of IgG in various groups studied by ICT:   
Studied groups NO  tested NO of + ve % 
Kidney Recipient 40 37 92.5 
Kidney donors 40 35 87.5 
Blood donors 80 66 82.5 
Total 160 138 85.0 
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CHAPTER FIVE 
DISCUSSION 
The potential for CMV infection must be considered for every 
patient undergoing solid organ transplantation. The source of these CMV 
infection include reactivation of the recipient's latent virus or virus from 
cells in the transplanted organ or blood (Pass, 2001). Nonetheless, 
serological tests for antibodies to CMV are useful for determining 
whether a patient had CMV infection in the past, a determinant of great 
clinical importance for the pretransplant evaluation of the prospective 
kidney transplant recipient and kidney and blood donors as indicated in 
tables (10, 11). In this survey we studied the prevalence of CMV 
antibodies among pretransplant kidney recipients (Group 1 and 4), 
kidney candidates donors (Group 2 and 5) and blood donors (Group 3 
and 6). To our surprise the prevalence of CMV IgG Abs is 96%, 92.5% 
in group (1 & 4), 92%, 87.5% in group (2 & 5) and 84%, 82.5% in group 
(3 & 6) (see table 10 and 13), suggesting high incidence of previous 
infection in all groups tested using ELISA and ICT respectively, and 
probably in the population at large. Furthermore in this study IgM 
ELISA was used to establish whether or not infection in the normal host 
has occurred recently. From table (5) the presence of CMV IgM Abs 
probably indicated active CMV infection as has been reported previously 
(Farrel et al., 1999). ELISA can detect CMV antibodies of both primary 
CMV and reactivation of latent infection. On the other hand high titer of 
CMV IgG antibody by ELISA (OD > 2.0) suggest recent exposure or 
reactivation of latent infection. The prevalence of CMV IgM was 10% in 
group 1, 17% in group 2 and 22% in group 3 (see table 11). This might 
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reflect an alarming picture of the disease in the population and indicates 
that seroconversion is an ongoing process. 
CMV one step test by ICT only indicates the presence of IgG 
antibodies to CMV in the serum sample and should not be used as the 
sole criteria for the diagnosis of CMV infection. From our result the 
intensity of the red colour in the test region in ICT may vary depending 
on the concentration of CMV antibodies present in the serum sample. 
Therefore, any shade or red colour that develops in the test region should 
be considered positive. In constant CMV ELISA control standard sera 
were included in the test and only cutt-off value of > 0.8 are considered 
positive.  
Furthermore, our study showed a very high concordance between 
ICT assay and ELISA for the detection of CMV IgG antibodies in the 
various groups studied. The correlation between these two assay systems 
for the detection of CMV IgG antibodies was 96%.  
Therefore, both assay (ELISA & ICT) were sensitive, specific and 
reliable for the detection of CMV IgG antibodies. The presence of these 
antibodies is considered as a marker for CMV infection. This is in 
agreement with Pass (2001).  
         Although the most common source of CMV infection in organ 
transplant patient is reactivation of transplant recipient's latent virus, and 
there is no means to prevent these infections, especially in our present 
situation where 96% of the patients have previous infection (Table 4 10 
and 13), selection of seronegative kidney donors for seronegative 
recipient will minimize primary CMV infection in kidney transplant 
recipient. However, this approach is not practical because of the 
restriction that it places on availability of seronegative donors. 
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Nonetheless preemptive ganciclovir therapy should be considered as a 
supporting procedure for the clearance of the virus just before kidney 
transplantation, which probably provides a cost-effective approach 
towards significantly improving the outcome of renal transplantation in 
CMV–seropositive patients.  
Factors that can activate latent virus in the recipient or the 
transplant include: intensive conditioning of the recipient with 
immunosuppressive drugs, minor HLA mismatched or concurrent 
microbial infection (Sayers et al., 1992). All these factors provoke 
proinflammatory reaction that leads to reactivation of latent virus as 
reported previously (Turgeon et al., 1998).  
As the prevalence of CMV Abs in blood donors group (3 & 6),was 
also high 84%, and 82.5% respectively  transmission of CMV through 
blood and blood products should be avoided by screening blood donors 
for CMV Abs. Blood from seronegative donor is an effective means of 
preventing transmission, however, it is clear from our present data 
screening and the selection process add significantly to the cost of 
preparing the blood products and may limit the availability of donor in 
the population where almost 84% of the blood donor's were seropositive 
(Table 10 and 13). As blood cells are the main source of CMV infection 
in peripheral blood, procedures that remove them from blood-products, 
should be introduced in our blood banks services in order to reduce the 
risk of CMV infection as described previously (Sayers et al., 1992) 
        In developed countries like USA approximately 50% of blood 
donors were CMV seronegative and a similar percentage was also 
reported in UK but only a small portion of CMV Abs positive donors 
transmit the virus through transfusion (Medical Sc. Ad. Council 2000).  
 55
Furthermore Raynor (1993) reported the prevalence of CMV Abs 
in 50 to 80% of the population in USA, 95% in India and 52% in 
Thailand. These data are comparable with our present findings. In France 
for instance 45% of antenatal women attending antenatal care centres 
were CMV seropositive, and 20% confirmed to have primary infection 
(Grangeat et al., 1995). In Belgium the risk of infecting a seronegative 
recipients being inseminated with seropositive semen was 21% (Liesnard 
et al., 1988). High incidence of CMV IgG Abs was also reported in 
Rumania (Myanovic, 1998). Furthermore high incidence of CMV IgG 
Abs was reported among AIDS patients (immunocompromized) in 
Brundi (Cochereau et al., 1999) and 93% was reported in the Sudan 
(Mohammed, 2000). All these data confirm the global prevalence of 
CMV in humans. Therefore, human CMV exhibit a ubiquitous pattern of 
distribution and efficient transmission via direct contact in all areas of 
the world regardless of socioeconomic condition as reported previously 
by Pass (1985). Nonetheless Pass (1985) also reported that in general 
prevalence is greater and CMV is acquired earlier in life in developing 
countries and in lower socioeconomic state of developed countries.  
         From the present study we found that the prevalence of CMV IgG 
antibodies increase with age approaching 96% in elderly persons (Fig 3). 
This is in agreement with the report of the Medical and Scientific 
Advisory Council (2000). On the other hand the prevalence of CMV 
IgM Abs was high in children and young adults and almost absent in 
elderly (Fig 4). This is in agreement of the finding of Babara (1993). A 
part from congenital infection and reactivation of CMV infection in renal 
transplant that lead to graft rejection, primary infection, life long latency 
and intermittent shedding commonly occur without any marked disease 
consequences. This led us to conclude that these characteristics 
underscore the remarkable balance this pathogen has developed in the 
host except in organ-transplant patients.                
 56
Conclusions: 
1. By ELISA we were able to measure the prevalence of CMV 
IgG and IgM Abs in patients waiting for kidney 
transplantation, kidney donor’s candidates and healthy blood 
donors. 
2. The prevalence of CMV IgG was found to be 96% in renal 
transplant recipient, 92% in kidney donor candidates and 84% 
in healthy blood donors, whereas the prevalence of CMV IgM 
Abs was found to be 10%, 17% and 22% in the respective 
group by ELISA. 
3. The prevalence of CMV IgG antibodies studied by ICT in the 
various groups (4, 5 & 6) was 92.5%, 87.5% and 82.5% 
respectively.  
4. The correlation between ICT (82%) and ELISA (89%) for the 
detection of CMV IgG antibodies was 96%. Therefore, both 
assay were sensitive and specific for the detection of CMV 
IgG antibodies  
5. CMV IgM Abs was high in children and young adults and 
almost absent in elderly suggesting seroconversion has been 
along ongoing process. 
6. The role of CMV infection in renal transplantation should be 
kept in consideration in every attempt for kidney 
transplantation and patients should be screened for CMV Abs 
and treated before transplantation.  
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Recommendations: 
1. All transplant patients should be screened, for CMV infection 
periodically. 
2. Organ and blood donors should be screened, for CMV 
infection. 
3. Our blood bank services should be developed to provide 
cotton-wool, filtered blood product without WBCs and 
platelets for transplant patients.  
4. All organ transplant patients at risk of CMV infection should 
be treated with gancyclovir for 3–4 month post transplantation. 
5. The Heamodialysis patients should be screened for CMV 
infection and those found positive should be put in a separate 
haemodialysis machine. 
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